EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease

Stefan Bartl, Yuanyun Xie, Nalini Potluri, Ratnesh Kesineni, Katlin Hencak, Louisa Dal Cengio, Katja Balazs, Abid Oueslati, Michela Parth, Nina Salhat, Alberto Siddu, Oskar Smrzka und 4 weitere

Neurobiology of Disease · 2024

DOI: 10.1016/j.nbd.2023.106376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurobiology of Disease, 2024. Verfasst von Stefan Bartl und 15 weiteren Autor:innen. Beteiligte Einrichtung: HD Immune, Vienna, Austria. Electronic address: S.bartl@HDImmune.com. Hauptthemen laut MEDLINE: Huntington Disease. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In Huntington disease (HD), the mutant huntingtin (mtHTT) protein is the principal cause of pathological changes that initiate primarily along the cortico-striatal axis. mtHTT is ubiquitously expressed and there is, accordingly, growing recognition that HD is a systemic disorder with functional interplay between the brain and the periphery. We have developed a monoclonal antibody, C6-17, targeting an exposed region of HTT near the aa586 Caspase 6 cleavage site. As recently published, mAB C6-17 can block cell-to-cell propagation of mtHTT in vitro. In order to reduce the burden of the mutant protein in vivo, we queried whether extracellular mtHTT could be therapeutically targeted in YAC128 HD mice. In a series of proof of concept experiments, we found that systemic mAB C6-17 treatment resulted in the distribution of the mAB C6-17 to peripheral and CNS tissues and led to the reduction of HTT protein levels. Compared to CTRL mAB or vehicle treated mice, the mAB C6-17 treated YAC128 animals showed improved body weight and motor behaviors, a delayed progression in motor deficits and reduced striatal EM48 immunoreactivity. These results provide the first proof of concept for the feasibility and therapeutic efficacy of an antibody-based anti-HTT passive immunization approach and suggest this modality as a potential new HD treatment strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseaseMiceAnimalsMice, TransgenicNerve Tissue ProteinsNuclear ProteinsHuntingtin ProteinImmunotherapyDisease Models, AnimalAntibodies, MonoclonalDisease Progression

Stichwörter der Autor:innen

Extracellular huntingtinHuntingtin lowering therapyHuntington diseaseImmunotherapyPassive immunizationPreclinical trialTransgenic mice

Substanzen

Nerve Tissue ProteinsNuclear ProteinsHuntingtin ProteinAntibodies, Monoclonal

Autor:innen und Institutionen

  • HD Immune, Vienna, Austria. Electronic address: S.bartl@HDImmune.com.
  • University of Central Florida, Burnett School of Biomedical Sciences, Orlando, FL, United States of America; University of British Columbia, Centre for Molecular Medicine and Therapeutics, Vancouver, Canada.
  • University of Central Florida, Burnett School of Biomedical Sciences, Orlando, FL, United States of America.
  • University of British Columbia, Centre for Molecular Medicine and Therapeutics, Vancouver, Canada.
  • AFFiRiS AG, Vienna, Austria.
  • Centre de recherche du CHU - Université Laval, Québec, Canada.

Zitieren

APA

Bartl, S., Xie, Y., Potluri, N., Kesineni, R., Hencak, K., Cengio, L. D., Balazs, K., Oueslati, A., Parth, M., Salhat, N., Siddu, A., Smrzka, O., Cicchetti, F., Straffler, G., Hayden, M. R., & Southwell, A. L. (2024). Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2023.106376

Vancouver

Bartl S, Xie Y, Potluri N, Kesineni R, Hencak K, Cengio LD, et al. Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease. Neurobiology of Disease. 2024. doi:10.1016/j.nbd.2023.106376

BibTeX
@article{Bartl2024,
  author = {Bartl, Stefan and Xie, Yuanyun and Potluri, Nalini and Kesineni, Ratnesh and Hencak, Katlin and Cengio, Louisa Dal and Balazs, Katja and Oueslati, Abid and Parth, Michela and Salhat, Nina and Siddu, Alberto and Smrzka, Oskar and Cicchetti, Francesca and Straffler, Günther and Hayden, Michael R and Southwell, Amber L},
  title = {Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease},
  journal = {Neurobiology of Disease},
  year = {2024},
  doi = {10.1016/j.nbd.2023.106376}
}
Kostenlos starten →